KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Operations (2016 - 2025)

West Pharmaceutical Services' Cash from Operations history spans 17 years, with the latest figure at 251100000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 32.09% year-over-year to 251100000.0; the TTM value through Dec 2025 reached 754800000.0, up 15.52%, while the annual FY2025 figure was 754800000.0, 15.52% up from the prior year.
  • Cash from Operations for Q4 2025 was 251100000.0 at West Pharmaceutical Services, up from 197200000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 251100000.0 in Q4 2025 and bottomed at 88700000.0 in Q1 2021.
  • The 5-year median for Cash from Operations is 171150000.0 (2022), against an average of 174635000.0.
  • The largest annual shift saw Cash from Operations skyrocketed 70.46% in 2022 before it decreased 21.73% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 160800000.0 in 2021, then surged by 43.53% to 230800000.0 in 2022, then increased by 3.6% to 239100000.0 in 2023, then fell by 20.49% to 190100000.0 in 2024, then skyrocketed by 32.09% to 251100000.0 in 2025.
  • Per Business Quant, the three most recent readings for WST's Cash from Operations are 251100000.0 (Q4 2025), 197200000.0 (Q3 2025), and 177100000.0 (Q2 2025).